多囊卵巢综合征合并肥胖女性减重后排卵恢复:BAMBINI随机对照试验事后分析
该研究为BAMBINI多中心随机对照试验的事后探索性分析,纳入75名多囊卵巢综合征合并肥胖女性,随访52周。结果显示50.8%实现排卵恢复,任何程度的总体重下降均与排卵恢复几率升高相关,未发现有害的上限阈值。
要点
- 任何程度的体重下降均与排卵恢复几率升高相关,未发现减重上限阈值。
- 体重每降低1%,排卵恢复的比值增加5.6%(OR 0.944,95%CI 0.900-0.990)。
- 基线抗苗勒管激素和总睾酮较高与排卵恢复几率降低相关。
核心结论
- 任何程度的总体重下降均与排卵恢复几率升高相关,未发现与排卵恢复降低相关的体重下降上限阈值。
主要发现
- 52周时50.8%(38/75)实现排卵恢复,无体重下降者排卵恢复率为19%,减重者超过50%。
- 体重每降低1%,排卵恢复的比值增加5.6%(OR 0.944,95%CI 0.900-0.990)。
- 基线血清抗苗勒管激素较高(OR 0.963,95%CI 0.938-0.988;P=0.004)和血浆总睾酮较高(OR 0.324,95%CI 0.142-0.742;P=0.008)与排卵恢复几率降低相关。
- 减重手术后更大程度的总体重下降与性激素结合球蛋白升高和游离雄激素指数降低相关。
关键数值与推荐
- 排卵恢复定义为52周随访期内相隔3-5周出现两次连续生化确认的排卵事件(血清孕酮≥16.0 nmol/l)。
- 纳入标准为多囊卵巢综合征、BMI≥35 kg/m2、稀发排卵或无排卵。
临床怎么用
- 对于多囊卵巢综合征合并肥胖且不急于妊娠的女性,可支持包括减重手术在内的减重策略以改善排卵恢复。
局限性
- 为探索性事后分析,非预设分析,未设计用于确定最佳或上限总体重下降阈值。
- 研究效能不足以检测更高程度体重下降时潜在的生殖不良效应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the frequency of ovulatory recovery (OvR) after different degrees of total weight loss (TWL) in women with polycystic ovary syndrome (PCOS) and obesity, and can an excessive degree of TWL be identified that is harmful to the chance of OvR? SUMMARY ANSWER: Any degree of TWL was associated with a higher likelihood of OvR, and no upper threshold of TWL associated with reduced OvR was identified. WHAT IS KNOWN ALREADY: Modest weight loss (5-10%) improves reproductive function in women with PCOS. However, the relationship between greater degrees of TWL and OvR remains uncertain. STUDY DESIGN, SIZE, DURATION: Secondary post hoc analysis of a multicentre, open-label, randomised controlled trial (BAMBINI) conducted in the UK between February 2020 and April 2023. Eighty women were randomised (1:1) to standard medical care or vertical sleeve gastrectomy. Seventy-five were included in this analysis and followed up for 52 weeks. PARTICIPANTS/MATERIALS, SETTING, METHODS: Participants had PCOS, a BMI of 35 kg/m2 or higher, and oligomenorrhea/amenorrhoea. OvR was defined as two consecutive biochemically confirmed ovulatory events (serum progesterone 16.0 nmol/l or higher), occurring 3-5 weeks apart within the 52 week follow up period. Associations between TWL, reproductive hormones, and OvR were analysed using logistic regression. Analyses were exploratory and not prespecified. MAIN RESULTS AND THE ROLE OF CHANCE: At 52 weeks, 50.8% (38/75) achieved OvR. OvR occurred in 19% of participants without weight loss and in >50% of those who lost weight. Each 1% reduction in body weight was associated with a 5.6% increase in the odds of OvR (OR 0.944, 95% CI 0.900-0.990). Higher baseline serum anti-Müllerian hormone (OR 0.963, 95% CI [0.938-0.988]; P = 0.004) and higher plasma total testosterone (OR 0.324, 95% CI [0.142-0.742]; P = 0.008) were associated with lower odds of OvR. Greater TWL following bariatric surgery was associated with increased sex hormone-binding globulin and reduced free androgen index. LIMITATIONS, REASONS FOR CAUTION: This was an exploratory post hoc analysis not designed to define optimal or upper TWL thresholds. The study was not powered to detect potential adverse reproductive effects at higher degrees of TWL. WIDER IMPLICATIONS OF THE FINDINGS: These findings suggest that OvR in women with PCOS and obesity improves progressively with increasing TWL, supporting weight loss strategies including bariatric surgery in appropriately selected women not seeking imminent pregnancy. STUDY FUNDING/COMPETING INTEREST(S): The Jon Moulton Charity Trust funded the BAMBINI trial. This work was supported by grants from the National Institute of Health Research (NIHR), the NIHR/Wellcome Trust Imperial Clinical Research Facility, and the NIHR Imperial Biomedical Research Centre. The Section of Endocrinology and Investigative Medicine was funded by grants from the Medical Research Council (MRC), Biotechnology and Biological Sciences Research Council (BBSRC), and the NIHR, and was supported by the NIHR Biomedical Research Centre Funding Scheme. The views expressed are those of the author(s) and not necessarily those of the MRC, the NHS, the NIHR, or the Department of Health. S.N.S.S. was supported by an Imperial post-doctoral post-CCT Fellowship. A.A. was supported by an NIHR Clinician Scientist Award CS-2018-18-ST2-002. All authors acknowledge infrastructure support for this research from the NIHR Imperial Biomedical Research Centre (BRC).A.D.M. has received research funding from the Medical Research Council (MRC), National Institute for Health and Care Research (NIHR), Jon Moulton Charitable Foundation, PEACEPLUS programme (EU and UK government), Anabio, Fractyl, Boehringer Ingelheim, Eli Lilly, Gila, Randox, and Novo Nordisk. A.D.M. has received honoraria for lectures and presentations from Novo Nordisk, AstraZeneca, Currax Pharmaceuticals, Boehringer Ingelheim, Screen Health, GI Dynamics, Algorithm, Eli Lilly, Ethicon, and Medtronic. A.D.M. is a shareholder in the Beyond BMI clinic, which provides clinical obesity care. H.R. is on the advisory board for Novo Nordisk and is the national lead for the REDEFINE 3 trial. TRIAL REGISTRATION NUMBER: N/A.
引用
- Samarasinghe SNS, Abbara A, Ortega PM, et al. Ovulatory Recovery following weight loss in women with polycystic ovary syndrome and obesity: a post hoc analysis of the BAMBINI randomised controlled trial. Hum Reprod. 2026. PMID: 41808368. doi:10.1093/humrep/deag037
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。